Breast Health

COVID-19

Cervical Health 

Contraception

Curbside Consults

Dermatology

Drug Pipeline News

Endometriosis

Genetic Testing

Gynecologic Oncology

Gynecology

Fetal Imaging

Abnormal Obstetrical Ultrasound

Ultrasound

Women's Imaging

Breast Imaging

Women's Ultrasound

Imaging

Infertility

LARC

Legally Speaking

Life Transitions

Malpractice

Menopause

Mental Health

Noninvasive Prenatal Testing

Obstetrics

Opinion

Osteoporosis

Pediatrics

Practice Management

Pregnancy and Birth

Sexual Health

Sexually Transmitted Infections

Surgery

Technology

Urology

Uterine Fibroids

Vulvovaginal Disease

Well Woman

About

News

Media

Podcasts

Insights

Medical World News

Peer Exchange

Peers & Perspectives

Videos

Conferences

Conference Coverage

Conference Listing

Publications

Contemporary OB/GYN® Journal

Digital Supplements

CME/CE

Resources

Physician Fact Sheets

Interactive Tools

Supplements and Featured Publications

Subscribe

Editorial Board

Partnerships

Articles

A novel ultrasound-based diagnostic algorithm with 98.1% sensitivity enables accurate stratification of patients with mesenchymal uterine malignancies, paving the way for personalized care.

Diagnostic algorithm improves detection of uterine malignancies

Evidence-based guidelines stress the importance of timely diagnosis, collaborative care, and maternal-infant safety in addressing the rising incidence of hematological malignancies in pregnancy.

Multidisciplinary care found key to managing blood cancers during pregnancy

Discover how FDA-approved self-collection and updated guidelines for cervical cancer screening are improving accessibility and empowering early prevention efforts.

Self-collection and extended genotyping advance cervical cancer screening

Jeff Andrews, MD, FRCSC, discusses troubling trends in cervical cancer mortality and how self-collection could address key barriers to screening, based on a recent BD survey conducted across 4 countries.

New trends in cervical cancer screening: Self-collection and barriers to adherence

Advertise

Contact Us

Job Board

Terms of Use

Privacy Policy

Do Not Sell My Personal Information

Contemporary OB/GYN

Facebook

LinkedIn

RSS Feed

Spotlight

A Psychedelic to Treat Postpartum Depression?

CMV: In the Know

RSV Roundtable

STIs

Supplement: Closing the Gap in Cervical Cancer Screening

Vaginismus: Managing a Misunderstood and Underdiagnosed Condition

Why vNOTES Make Sense for My Patients

1rem

Authors

The pandemic’s profound impact on the industry has only heightened with staffing shortages and health care legislation complexities.

"Future proofing" health care

Saying "obstetrician-gynecologist" is a mouthful for most people, and it's probably the most abbreviated specialty in medicine, both spoken and written. However, there doesn't seem to be a consensus on how to pronounce OB-GYN. First, is it the two-syllable "O-B" or the monosyllabic "Ob"? Second, is it "gin" or "gyne" (like "Lyme")? I wonder if you have a preference. I know I do.

Almost nobody says "obstetrician-gynecologist" when speaking about these specialist physicians. But what's the "correct" way to pronounce OB/GYN?

Is It Ob-Gin or Ob-Gyne?

A 27-year-old woman presents with an 18-month history of vulvar irritation. She is otherwise healthy except for episodes of depression. She has tried multiple agents for her condition including topical steroids, Vagisil, antibiotics, and fluconazole. She used oral steroids but developed knee pain. Tacrolimus has not helped. A biopsy revealed lichen simplex chronicus. Immunofluorescent studies were negative.

A 27-year-old woman presents with an 18-month history of vulvar irritation. She has tried multiple agents for her condition including topical steroids, Vagisil, antibiotics, and fluconazole without relief. What's your diagnosis?

Vulvar irritation in a 27-year-old woman

Importance of HPV Screening

Video content above is prompted by the following:

What are the benefits and limitations of HPV self-collection, and who is it particularly designed for?

How does the sensitivity of HPV self-collection compare with traditional collection methods?

How can education about HPV and HPV screening influence screening rates?

The panelist discusses the cautions around recent FDA approvals on human papillomavirus (HPV) self-collection, including limitations and sensitivity while emphasizing the importance of patients continuing to see their OB/GYN regularly.

HPV Self-Collection Screening: What OB/GYNs Should Know

These are 3D ultrasound images of a 14-week fetus. What is your diagnosis?

occipital meningocele and umbilical hernia

Clinical

DailyDx: 3D Images of a 14-week fetus

Neurokinin and Estrogen Balance in Menopausal Hot Flashes for Primary Care

How can we simplify the physiology of KNDY neurons and roles of NK receptors for better understanding among primary care physicians?

Note: NK3 antagonism targets VMS (hot flashes); NK1 antagonism impacts sleep and night sweats

Note: Fezolinetant, a selective NK3 antagonist, reduces hot flashes

Note: Elinzanetant, in addition to reducing hot flashes (via NK3 antagonism) is also an NK1 antagonist which improves sleep disturbances and night sweats

Panelists discuss how to simplify the physiology of KNDy neurons and neurokinin (NK) receptors for primary care physicians, explaining how NK3 antagonism reduces hot flashes, while NK1 antagonism helps alleviate sleep disturbances and night sweats, with fezolinetant and elinzanetant serving as key nonhormonal treatment options.

Peers and Perspectives

Fezolinetant Guidelines and Emerging Data on Menopause and Liver Health

Why was a warning about serious liver injury added to the prescribing information for fezolinetant? (ie, postmarketing case of drug-induced liver injury)

Note: Clarify that when fezolinetant first came out, it had guidelines for baseline liver testing. But in the past month, this was updated- discuss update and what this means for patients/ physicians.

What baseline hepatic laboratory tests are recommended before patients start fezolinetant, and how often should they be monitored?

What symptoms or clinical laboratory values indicate that fezolinetant should be discontinued?

What are important discussion points to address patient concerns on liver health?

Panelists discuss why a warning about serious liver injury was added to the prescribing information for fezolinetant following a postmarketing case of drug-induced liver injury, and review updated guidelines for baseline liver testing, recommended monitoring, symptoms indicating the need to discontinue the medication, and key points for addressing patient concerns about liver health.

Rob Schile

Articles

Latest Updated Articles